Immunodeficiency 81 (IMD81) Cell Models for Research

Immunodeficiency 81 (IMD81) is a rare primary immunodeficiency disorder caused by mutations in the CD3E gene. It is characterized by severe T-cell lymphopenia and recurrent infections. The exact prevalence is unknown, but it is extremely rare, with only a few dozen cases reported worldwide. Patients typically present in infancy with severe combined immunodeficiency (SCID) phenotype, requiring hematopoietic stem cell transplantation for survival. Without treatment, the condition is fatal in early childhood. The clinical impact is profound, affecting multiple organ systems due to recurrent infections.

IMD81 serves as an excellent model for studying T-cell development, TCR signaling, and immune synapse formation. The CD3E gene encodes the epsilon subunit of the T-cell receptor (TCR) complex, which is essential for TCR expression and signal transduction. Research on IMD81 can provide insights into fundamental immunology, including thymocyte selection and peripheral T-cell activation. Public datasets, such as those from the International Union of Immunological Societies (IUIS) and ClinVar, provide mutation data. Open questions include the molecular mechanisms of partial versus complete CD3E deficiency and potential gene therapy approaches.

Although IMD81 is not a cancer, the molecular pathways involved are critical for immune function. The TCR signaling pathway is the primary pathway affected. Key steps include:

1. TCR engagement by peptide-MHC complexes.

2. Activation of Lck and Fyn kinases.

3. Phosphorylation of ITAMs on CD3 chains.

4. Recruitment of ZAP-70 and activation of downstream signaling.

5. Activation of calcium flux, NFAT, NF-κB, and MAPK pathways.

Defects in CD3E disrupt this cascade, leading to impaired T-cell activation and development.

Data from ClinVar and literature reports indicate that most IMD81 cases are due to biallelic loss-of-function mutations in CD3E.

The TCR signaling network is severely impaired in IMD81. Key nodes affected include:

• • TCR complex: Reduced expression of TCR on cell surface.
• • Lck/Fyn kinases: Reduced activation due to lack of CD3E.
• • ZAP-70: Impaired recruitment and activation.
• • LAT and SLP-76: Reduced phosphorylation.
• • Calcium signaling: Impaired NFAT activation.
• • NF-κB and MAPK pathways: Reduced activation.

These disruptions lead to a block in T-cell development at the double-negative to double-positive stage.

Organoids derived from patient iPSCs can recapitulate T-cell development, providing a more physiologically relevant model.

• • CD3E knockout mouse: Shows severe T-cell deficiency, mimicking IMD81.
• • CD3E-humanized mouse: Expresses human CD3E, useful for testing human-specific therapies.
• • Patient-derived xenograft (PDX) models: Not commonly used for IMD81 due to the nature of the disease, but can be generated from patient hematopoietic stem cells.

CRISPR-engineered isogenic cell lines with CD3E knockout or point mutations are valuable tools for studying IMD81. For example, a CD3E knockout Jurkat cell line can be used to study TCR signaling in the absence of CD3E. Knock-in lines with specific patient mutations (e.g., p.Arg90Ter) allow modeling of genotype-phenotype correlations. These models are commercially available and sequence-verified, accelerating research without the need for primary patient samples.

Gene-edited cell lines with CD3E knockout or knock-in mutations enable functional validation of genetic variants. For example, introducing a patient-specific mutation into a wild-type cell line can confirm its pathogenicity. Conversely, rescuing CD3E expression in knockout cells can restore TCR signaling, confirming the gene's role.

Isogenic pairs (wild-type vs. CD3E knockout) can be used to screen for compounds that bypass CD3E deficiency or enhance TCR signaling. This is relevant for developing therapies for immunodeficiencies and for understanding resistance mechanisms in T-cell-based immunotherapies.

CRISPR screens using CD3E knockout cells can identify synthetic lethal partners or genes that compensate for CD3E loss. This can reveal novel therapeutic targets for immunodeficiencies and T-cell malignancies.